Results 251 to 260 of about 175,041 (315)

Spontaneous regression of equine sarcoids is an exceptional event

open access: yesEquine Veterinary Journal, Volume 58, Issue 4, Page 889-894, July 2026.
Abstract Sarcoids are benign, yet locally aggressive skin tumours that commonly affect horses and other equid species. The lesions are induced by bovine papillomavirus types 1, 2, and probably 13 in conjunction with other factors including trauma and a genetic predisposition.
Sabine Brandt
wiley   +1 more source

Cervical cancer and screening: Knowledge, attitudes, and adherence among university students in Italy. [PDF]

open access: yesHum Vaccin Immunother
Angelillo S   +3 more
europepmc   +1 more source

Unintended Consequences of Life‐Saving Pharmaceutical Innovations: How HAART Led to the Resurgence of Syphilis

open access: yesHealth Economics, Volume 35, Issue 7, Page 1118-1130, July 2026.
ABSTRACT Syphilis, a sexually transmitted infection that can lead to serious health complications, was almost eliminated in the United States by 2000. But since then, its incidence began to increase, recently reaching a 60‐year peak. We suggest that the introduction of the highly active antiretroviral therapy (HAART) drug regimen, which transformed HIV
David Beheshti   +2 more
wiley   +1 more source

How Would You Treat? A Case‐Vignette Study of Provider Treatment Preferences in Human Papillomavirus‐Mediated Oropharyngeal Cancer

open access: yesHead &Neck, Volume 48, Issue 7, Page 1770-1778, July 2026.
ABSTRACT Background Current guidelines recommend surgical resection, definitive radiotherapy (RT), or concurrent chemoradiotherapy (CRT) for human papillomavirus (HPV)‐associated oropharyngeal squamous cell carcinoma (OPSCC). This study aimed to provide insight into practice patterns of providers who treat HPV‐associated OPSCC.
Sindhura Sridhar   +2 more
wiley   +1 more source

A new model for cervical cancer screening in Cambodian garment workers. [PDF]

open access: yesBMJ Glob Health
Thay S   +16 more
europepmc   +1 more source

A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. [PDF]

open access: yesOncotarget
Bivens E   +21 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy